Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Debio 0633
- Development stage
- Preclinical
- Lead developer
- Debiopharm
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Debio 0633 is a potential first-in-class antibody-drug conjugate (ADC) being developed by Debiopharm for the treatment of various cancers. It utilizes Debiopharm's proprietary Multilink™ technology, a cleavable linker platform designed for multidrug attachment, which enables high drug-to-antibody ratios (DAR) and enhanced metabolic stability. While the specific biological target remains undisclosed, the ADC is designed to address multiple tumor types with high unmet medical needs. The program is currently in the drug discovery phase, focusing on optimizing medicinal chemistry and stability for oncology applications.
Beyond the preview
Go deeper on Debio 0633.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Debio 0633.